16 Months' Longer Survival with Addition of Pertuzumab in Advanced Breast Cancer (FREE)

By Kelly Young Edited by Susan Sadoughi, MD, and André Sofair, MD, MPH Adding pertuzumab (Perjeta) to docetaxel and trastuzumab (Herceptin) as a first-line treatment was associated with …
Source: Physician's First Watch current issue - Category: Primary Care Source Type: news